A multicentre, observational cohort study to determine the efficacy and safety of lumacaftor/ivacaftor in patients with severe lung disease and cystic fibrosis

K. Tong (Newcastle, NSW, Australia), D. Dorahy (Newcastle, NSW, Australia), M. France (Brisbane, QLD, Australia), L. Burr (Brisbane, QLD, Australia), H. Greville (Adelaide, SA, Australia), S. Visser (Sydney, NSW, Australia), P. Middleton (Sydney, NSW, Australia), C. Wainwright (Brisbane, QLD, Australia), D. Barker (Newcastle, NSW, Australia), P. Wark (Newcastle, NSW, Australia)

Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis
Session: Advances in care and monitoring of cystic fibrosis
Session type: Oral Presentation
Number: 2126
Disease area: Paediatric lung diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Tong (Newcastle, NSW, Australia), D. Dorahy (Newcastle, NSW, Australia), M. France (Brisbane, QLD, Australia), L. Burr (Brisbane, QLD, Australia), H. Greville (Adelaide, SA, Australia), S. Visser (Sydney, NSW, Australia), P. Middleton (Sydney, NSW, Australia), C. Wainwright (Brisbane, QLD, Australia), D. Barker (Newcastle, NSW, Australia), P. Wark (Newcastle, NSW, Australia). A multicentre, observational cohort study to determine the efficacy and safety of lumacaftor/ivacaftor in patients with severe lung disease and cystic fibrosis. 2126

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study
Source: ERJ Open Res, 6 (1) 00172-2019; 10.1183/23120541.00172-2019
Year: 2020



The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study
Source: Eur Respir J, 53 (3) 1801587; 10.1183/13993003.01587-2018
Year: 2019



Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: A retrospective observational study
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010


Tiotropium discontinuation in patients with early-stage COPD: a prospective observational cohort study
Source: ERJ Open Res, 5 (1) 00175-2018; 10.1183/23120541.00175-2018
Year: 2019



Multi-institutional prospective cohort study of prognostic factors in patients with idiopathic pulmonary fibrosis receiving long-term oxygen therapy.
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019


The prevalence and diversity of fungi in respiratory samples of cystic fibrosis patients – a Dutch, nationwide, prospective, multicentre study
Source: International Congress 2018 – Latest developments in cystic fibrosis
Year: 2018



A real life multicenter national study on the use of nintedanib in moderate to severe IPF patients
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017


PEGASUS - the effects of commercial air travel on patients suffering from pulmonary hypertension - a prospective, multicenter, multinational study
Source: International Congress 2018 – Clinical aspects of pulmonary hypertension
Year: 2018

Prospective observational study in patients with obstructive lung disease: NOVELTY design
Source: ERJ Open Res, 5 (1) 00036-2018; 10.1183/23120541.00036-2018
Year: 2019



Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study
Source: ERJ Open Res, 8 (1) 00443-2021; 10.1183/23120541.00443-2021
Year: 2022



A single-center observational study assessing response to mepolizumab in severe eosinophilic asthma
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019

Aspergillus pulmonary disease in cystic fibrosis (CF) patients: multicentre perspective observational study based on new diagnostic tests to evaluate the prognostic value on the CF disease
Source: Virtual Congress 2021 – Adult cystic fibrosis
Year: 2021



A feasibility, randomised controlled trial of a complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): study protocol
Source: ERJ Open Res, 5 (4) 00186-2019; 10.1183/23120541.00186-2019
Year: 2019



The effects of pulmonary rehabilitation in patients with non-cystic fibrosis bronchiectasis- A randomised controlled trial
Source: International Congress 2017 – Best abstracts in pulmonary rehabilitation and chronic care
Year: 2017




Do patients with cystic fibrosis participating in clinical trials demonstrate placebo response ? A meta-analysis.
Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis
Year: 2019



A multicentre cohort study on the association between common markers of asthma and the incidence of COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 295s
Year: 2006

A randomized, double-blind, placebo-controlled, phase III study of the safety and efficacy of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases
Year: 2007


1-year prospective study in severe COPD patients: marker of inflammation, lung function and radiologic evaluation
Source: Annual Congress 2007 - Pathophysiology and assessment of COPD
Year: 2007


The evaluation of the efficacy and safety of phospholipids‘ inhalation in patients with bronchial asthma (BA): A prospective randomized placebo-controlled study
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012

PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients
Source: International Congress 2016 – IPF clinical
Year: 2016